Contact
searchSearch
HMP Global
Login

Advertisement

ADVERTISEMENT

Videos

Melissa Johnson, MD, Tennessee Oncology
Videos
Sotorasib Significantly Improves PFS vs Docetaxel in Patients With KRAS G12C-Mutated NSCLC
11/10/2022
Melissa Johnson, MD, discusses results from the phase 3 CodeBreaK 200 trial comparing sotorasib vs docetaxel for patients with previously treated NSCLC with a KRAS G12C mutation.
Melissa Johnson, MD, discusses results from the phase 3 CodeBreaK 200 trial comparing sotorasib vs docetaxel for patients with previously treated NSCLC with a KRAS G12C mutation.
Melissa Johnson, MD, discusses...
11/10/2022
Oncology
Carrie Langstraat, MD
Videos
HIPEC: Standard of Care for Ovarian Cancer?
11/08/2022
Carrie Langstraat, MD, discusses whether HIPEC should be considered the standard of care for ovarian cancer, a subject she debated at the 2022 Great Debates and Updates in Women’s Oncology virtual meeting.
Carrie Langstraat, MD, discusses whether HIPEC should be considered the standard of care for ovarian cancer, a subject she debated at the 2022 Great Debates and Updates in Women’s Oncology virtual meeting.
Carrie Langstraat, MD, discusses...
11/08/2022
Oncology
Sara Hurvitz, MD
Videos
The Importance of Right Sizing Early HER2 Breast Cancer Treatment
11/07/2022
Sara Hurvitz, MD, discusses the importance of right sizing early HER2 treatment for patients with HER2-positive breast cancer, a topic she presented at the 2022 Great Debates and Updates in Women's Oncology virtual meeting.
Sara Hurvitz, MD, discusses the importance of right sizing early HER2 treatment for patients with HER2-positive breast cancer, a topic she presented at the 2022 Great Debates and Updates in Women's Oncology virtual meeting.
Sara Hurvitz, MD, discusses the...
11/07/2022
Oncology

Advertisement

Helena Yu, MD
Videos
EGFR: First Line, Second Line and Beyond in the Age of Osimertinib
11/07/2022
Helena Yu, MD, shares exciting new developments and potential treatments in the first- and second-line settings for patients with EGFR-mutated lung cancer, a topic she presented at the 2022 Great Debates and Updates in Lung Cancer.
Helena Yu, MD, shares exciting new developments and potential treatments in the first- and second-line settings for patients with EGFR-mutated lung cancer, a topic she presented at the 2022 Great Debates and Updates in Lung Cancer.
Helena Yu, MD, shares exciting...
11/07/2022
Oncology
Sujit Sheth, MD
Videos
Novel Therapies for Non–Transfusion-Dependent and Transfusion-Dependent Thalassemia
11/03/2022
Sujit Sheth, MD, explains the pathophysiology of thalassemia and outlines novel therapies addressing unmet needs in this treatment landscape, including therapies with curative intent and those without curative intent.
Sujit Sheth, MD, explains the pathophysiology of thalassemia and outlines novel therapies addressing unmet needs in this treatment landscape, including therapies with curative intent and those without curative intent.
Sujit Sheth, MD, explains the...
11/03/2022
Oncology
Andrea Necchi, MD, San Raffaele Hospital
Videos
3-Year Efficacy of Neoadjuvant Pembrolizumab Before Radical Cystectomy For Muscle-Invasive Bladder Cancer
11/03/2022
Andrea Necchi, MD, shares follow-up data from the phase 2 PURE-01 trial, confirming the sustained efficacy of neoadjuvant pembrolizumab before radical cystectomy in patients with muscle-invasive urothelial bladder cancer.
Andrea Necchi, MD, shares follow-up data from the phase 2 PURE-01 trial, confirming the sustained efficacy of neoadjuvant pembrolizumab before radical cystectomy in patients with muscle-invasive urothelial bladder cancer.
Andrea Necchi, MD, shares...
11/03/2022
Oncology

Advertisement

Norman Latov, MD
Videos
Managing Peripheral Neuropathies Associated With Waldenström Macroglobulinemia
11/02/2022
Norman Latov, MD, outlines the types of peripheral neuropathies associated with Waldenström macroglobulinemia and IgM monoclonal gammopathies and discusses available therapies for managing these complications.
Norman Latov, MD, outlines the types of peripheral neuropathies associated with Waldenström macroglobulinemia and IgM monoclonal gammopathies and discusses available therapies for managing these complications.
Norman Latov, MD, outlines the...
11/02/2022
Oncology
Lorenzo Falchi, MD
Videos
Subcutaneous Epcoritamab With Rituximab and Lenalidomide for Relapsed/Refractory Follicular Lymphoma
11/02/2022
Lorenzo Falchi, MD, presents updated findings from a phase 1/2 trial exploring subcutaneous epcoritamab combined with rituximab and lenalidomide for patients with relapsed/refractory follicular lymphoma.
Lorenzo Falchi, MD, presents updated findings from a phase 1/2 trial exploring subcutaneous epcoritamab combined with rituximab and lenalidomide for patients with relapsed/refractory follicular lymphoma.
Lorenzo Falchi, MD, presents...
11/02/2022
Oncology
Morie Gertz, MD
Videos
Do All Patients Diagnosed With Waldenström Macroglobulinemia Require Immediate Intervention?
11/02/2022
Morie Gertz, MD, discusses options for managing patients with Waldenström macroglobulinemia, highlighting that not all patients diagnosed with the disease require immediate intervention.
Morie Gertz, MD, discusses options for managing patients with Waldenström macroglobulinemia, highlighting that not all patients diagnosed with the disease require immediate intervention.
Morie Gertz, MD, discusses...
11/02/2022
Oncology

Advertisement

Lipika Goyal, MD, Stanford Cancer Center
Videos
Futibatinib Receives FDA Approval for Intrahepatic Cholangiocarcinoma With FGFR2 Fusions and Rearrangements
10/31/2022
Lipika Goyal, MD, shares her insight about the recent FDA approval of futibatinib for patients with intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements and discusses findings from the FOENIX-CCA2 trial, which led to the approval.
Lipika Goyal, MD, shares her insight about the recent FDA approval of futibatinib for patients with intrahepatic cholangiocarcinoma with FGFR2 fusions/rearrangements and discusses findings from the FOENIX-CCA2 trial, which led to the approval.
Lipika Goyal, MD, shares her...
10/31/2022
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Recent News

News
Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation
08/08/2024
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.
Results from a phase 2 study...
08/08/2024
Oncology
FDA Approval
FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma
08/08/2024
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.
The US Food and Drug...
08/08/2024
Oncology
News
Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer
08/07/2024
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.
According to results from the...
08/07/2024
Oncology
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
News
Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer
08/07/2024
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.
Results from a phase 2 study...
08/07/2024
Oncology
FDA Approval
FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma
08/06/2024
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.
Based on results from the INDIGO...
08/06/2024
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma
08/02/2024
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...
On August 2, 2024, the US Food...
08/02/2024
Oncology
FDA Approval
FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer
08/01/2024
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.
The FDA approved dostarlimab...
08/01/2024
Oncology
News
Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML
08/01/2024
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.
The first-line combination of...
08/01/2024
Oncology
News
Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
08/01/2024
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...
In the phase 1 trial, the...
08/01/2024
Oncology

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use